Open AccessSUN-334 Evaluation of the CCK-2 Receptor Agonist 177Lu-PP-F11N for PRRT of Medullary Thyroid Carcinoma: Results of a Phase 0 "Lumed" Study
Author(s) -
Christof Rottenburger,
Guillaume Nicolas,
Lisa McDougall,
Felix Kaul,
Michal Cachovan,
Roger Schibli,
Susanne Geistlich,
Martin Béhé,
Damian Wild,
Emanuel Christ
Publication year - 2019
Publication title -
journal of the endocrine society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.046
H-Index - 20
ISSN - 2472-1972
DOI - 10.1210/js.2019-sun-334
Subject(s) - radionuclide therapy , medicine , nuclear medicine , bone marrow , dosimetry , thyroid carcinoma , medullary cavity , thyroid , adverse effect
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom